Rosen Law Firm has initiated a securities class action lawsuit against REGENXBIO, Inc., targeting investors who purchased company securities during a four-year window spanning from February 9, 2022, through January 27, 2026. The litigation centers on allegations that company officials made materially false and misleading statements regarding the efficacy and safety profile of RGX-111, an investigational gene therapy treatment for Hurler syndrome, while simultaneously withholding adverse information that emerged during clinical trials.
The defendant is accused of failing to disclose material trial setbacks and safety concerns that would have been reasonably important to investors evaluating the company's prospects and the viability of its lead therapeutic candidate. This omission reportedly created a false impression regarding the commercial potential of REGENXBIO's gene therapy pipeline and the overall financial trajectory of the company.
Investors who acquired REGENXBIO securities during the specified timeframe and wish to participate in the litigation as lead plaintiffs must file the necessary documentation by April 14, 2026. Legal counsel specializing in securities law is recommended for shareholders seeking to understand their rights and potential remedies in this action.